MVA

News MVA

• Bavarian Nordic Receives NIH Grant to Investigate the Potential of an MVA-BN based Vaccine against Ebola and Marburg Viruses

  Bavarian Nordic A/S announced that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus). As previously announced, the company is investigating the potential use of its core vaccine technology, MVA-B more

• Bavarian Nordic's MVA-BN patent stands in European validity challenge

  Bavarian Nordic A/S announced that the company successfully defended its core patent covering the MVA-BN® technology despite aggressive attempts from competitors to revoke the patent in Europe. The patent was granted in December 2005 and after the nine month opposition period in which any third pa more

• Transgene Announces Opening of First Clinical Site for its Phase II Trial of TG4040 for the Treatment of Chronic Hepatitis C

  Transgene S.A. announced the opening of the first clinical site for the phase II trial (named HCVac) of TG4040 (MVA-HCV) for the treatment of naïve genotype 1 hepatitis C infected patients in combination with standard of care (Pegylated-Interferon Alpha and Ribavarin). HCVac is a phase II randomiz more

Publications MVA

• Network Analysis of the MVA and MEP Pathways for Isoprenoid Synthesis

  Isoprenoid biosynthesis is essential for all living organisms, and isoprenoids are also of industrial and agricultural interest. All isoprenoids are derived from prenyl diphosphate (prenyl-PP) precursors. Unlike isoprenoid biosynthesis in other living organisms, prenyl-PP, as the precursor of all is more

• Towards a universal influenza vaccine: Volunteer virus challenge studies in quarantine to speed the development and subsequent licensing

  Abstract There are now more than ten experimental vaccine formulations which induce T and B cell immunity towards the internally situated virus proteins matrix (M1 and M2e) and nucleoprotein (NP), and towards stem and stalk regions of the HA which have a shared antigenic structure amongst many o more

• Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and ...

  by Caroline Ogwang, Muhammed Afolabi, Domtila Kimani, Ya Jankey Jagne, Susanne H. Sheehy, Carly M. Bliss, Christopher J. A. Duncan, Katharine A. Collins, Miguel A. Garcia Knight, Eva Kimani, Nicholas A. Anagnostou, Eleanor Berrie, Sarah Moyle, Sarah C. Gilbert, Alexandra J. Spencer, Peninah Soipei, more

Market studies MVA

• Bavarian Nordic A/S (BAVA) - Financial and Strategic SWOT Analysis Review

  Bavarian Nordic A/S (Bavarian Nordic) is a publicly held bio pharmaceutical company developing and producing vaccines for the treatment and prevention of life-threatening diseases. The company primarily focuses on areas of biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and more

Websites MVA